Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rangering i aksjer #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Aksjekurs
$0.28545656
Markedsverdi
$4.50M
Endring (1 dag)
5.97%
Endring (1 år)
0.00%
Land
FR
Handel Acticor Biotech SAS (ALACT)

Kategori

EPS for Acticor Biotech SAS (ALACT)
EPS per June 2024 TTM: $-1.95
Ifølge de siste økonomiske rapportene og aksjekursen til Acticor Biotech SAS er selskapets nåværende EPS (TTM) $-1.95. Ved slutten av 2022 hadde selskapet en EPS på $-1.62, en nedgang sammenlignet med EPS-en i 2021 som var $-1.84.
EPS-historikk for Acticor Biotech SAS fra 2010 til 2026
EPS ved slutten av hvert år
År EPS Endre
2026 (TTM) $-1.95 -99.90%
2023 0.00 -99.90%
2022 $-1.62 -12.08%
2021 $-1.84 26.05%
2020 $-1.46 35.69%
2019 $-1.08 -51.93%
2018 $-2.24 -40.33%
2017 $-3.76 2,449.69%
2016 $-0.15 -66.91%
2015 $-0.45 26.87%
2014 $-0.35 -143.25%
2013 $0.81 -9.55%
2012 $0.90 35.87%
2011 $0.66 462.35%
2010 $0.12 0.00%
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$3.62 -285.38%
DK
$15.47 -891.71%
US
$43.12 -2,306.76%
US
$9.62 -592.36%
BE
$2.98 -252.51%
AU